• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2019 年回顾:系统性硬化症。

One year in review 2019: systemic sclerosis.

机构信息

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

Rheumatology Unit, University of Florence, Italy.

出版信息

Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):3-14. Epub 2019 Oct 3.

PMID:31587697
Abstract

Systemic sclerosis (SSc) is a complex disorder characterised by the involvement of small arteries, microvessels and connective tissue, with deposition of fibrotic tissue and microvascular obliteration in the skin and internal organs. Due to the multifaceted nature of the disease, several articles are published in the medical literature every year, aimed at exploring different aspects of the pathogenesis, internal organ involvement and clinical aspects, and possible therapeutic approaches. In this article we have reviewed the literature on SSc of the past year, with the aim of identifying novel approaches that may help the treating physician in the clinical management of patients.

摘要

系统性硬化症(SSc)是一种复杂的疾病,其特征为小动脉、微血管和结缔组织受累,皮肤和内脏器官中纤维组织沉积和微血管闭塞。由于疾病的多方面性质,每年都有许多文章在医学文献中发表,旨在探讨发病机制、内脏器官受累和临床方面的不同方面,以及可能的治疗方法。在本文中,我们回顾了过去一年中关于 SSc 的文献,目的是确定新的方法,以帮助治疗医生对患者进行临床管理。

相似文献

1
One year in review 2019: systemic sclerosis.2019 年回顾:系统性硬化症。
Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):3-14. Epub 2019 Oct 3.
2
Macro- and microvascular disease in systemic sclerosis.系统性硬化症中的大血管和微血管疾病。
Vascul Pharmacol. 2015 Aug;71:16-23. doi: 10.1016/j.vph.2015.05.015. Epub 2015 Jun 2.
3
Emerging diagnostic and therapeutic challenges for skin fibrosis in systemic sclerosis.系统性硬化症皮肤纤维化新出现的诊断和治疗挑战
Mol Aspects Med. 2024 Apr;96:101252. doi: 10.1016/j.mam.2024.101252. Epub 2024 Feb 6.
4
Progressive loss of lymphatic vessels in skin of patients with systemic sclerosis.系统性硬化症患者皮肤淋巴管渐进性丧失。
J Rheumatol. 2011 Feb;38(2):297-301. doi: 10.3899/jrheum.100767. Epub 2010 Nov 15.
5
Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin.系统性硬化症的原发性心肌受累:微血管起源的证据。
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 62):S48-53. Epub 2010 Nov 3.
6
One year in review 2020: systemic sclerosis.2020 年回顾:系统性硬化症。
Clin Exp Rheumatol. 2020 May-Jun;38 Suppl 125(3):3-17. Epub 2020 Jul 6.
7
Assessing microvascular changes in systemic sclerosis diagnosis and management.评估系统性硬化症诊断和管理中的微血管变化。
Nat Rev Rheumatol. 2010 Oct;6(10):578-87. doi: 10.1038/nrrheum.2010.104. Epub 2010 Aug 10.
8
Targeting interferons as a strategy for systemic sclerosis treatment.以干扰素为靶点的系统性硬化症治疗策略。
Immunol Lett. 2018 Mar;195:45-54. doi: 10.1016/j.imlet.2017.10.011. Epub 2017 Oct 26.
9
Systemic sclerosis: one year in review 2024.系统性硬皮病:2024 年回顾一年
Clin Exp Rheumatol. 2024 Aug;42(8):1517-1528. doi: 10.55563/clinexprheumatol/is29he. Epub 2024 Jul 26.
10
[Systemic sclerosis--pathogenesis, clinical manifestations and treatment].[系统性硬化症——发病机制、临床表现及治疗]
Lijec Vjesn. 2010 May-Jun;132(5-6):162-8.

引用本文的文献

1
Widespread mutagenesis and chromosomal instability shape somatic genomes in systemic sclerosis.系统性硬化症中广泛的突变和染色体不稳定性塑造了体细胞基因组。
Nat Commun. 2024 Oct 15;15(1):8889. doi: 10.1038/s41467-024-53332-z.
2
Psychometric analysis and validation of the Persian translation of the systemic sclerosis questionnaire (SySQ).系统性硬化症问卷(SySQ)波斯语翻译的心理测量分析与验证
J Educ Health Promot. 2024 Jul 11;13:234. doi: 10.4103/jehp.jehp_494_23. eCollection 2024.
3
Clinical course and factors associated with progressive acro-osteolysis in early systemic sclerosis: a retrospective cohort study.
早期系统性硬化症中进行性肢端骨溶解的临床病程和相关因素:一项回顾性队列研究。
Sci Rep. 2024 Mar 1;14(1):5129. doi: 10.1038/s41598-024-55877-x.
4
Immunologic and nonimmunologic sclerodermal skin conditions - review.免疫性和非免疫性硬皮病皮肤状况——综述。
Front Immunol. 2023 Jul 12;14:1180221. doi: 10.3389/fimmu.2023.1180221. eCollection 2023.
5
Comorbidity and mortality in systemic sclerosis and matched controls: Impact of interstitial lung disease. A population based cohort study based on health registry data.系统性硬皮病及匹配对照患者的合并症和死亡率:间质性肺病的影响。一项基于健康登记数据的基于人群队列研究。
Chron Respir Dis. 2023 Jan-Dec;20:14799731231195041. doi: 10.1177/14799731231195041.
6
Hub genes, diagnostic model, and predicted drugs in systemic sclerosis by integrated bioinformatics analysis.通过综合生物信息学分析确定系统性硬化症中的枢纽基因、诊断模型及预测药物
Front Genet. 2023 Jul 12;14:1202561. doi: 10.3389/fgene.2023.1202561. eCollection 2023.
7
PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients.PPARγ 部分激动剂 LPSF/GQ-16 可预防次氯酸诱导的系统性硬化症(SSc)中的皮肤和肺纤维化,并调节 SSc 患者外周血单核细胞中的细胞因子产生。
Inflammopharmacology. 2024 Feb;32(1):433-446. doi: 10.1007/s10787-023-01296-9. Epub 2023 Jul 21.
8
Mesenchymal Stem/Stromal Cell-Based Therapies in Systemic Rheumatic Disease: From Challenges to New Approaches for Overcoming Restrictions.基于间充质干细胞/基质细胞的系统性风湿病治疗:从挑战到克服限制的新方法。
Int J Mol Sci. 2023 Jun 15;24(12):10161. doi: 10.3390/ijms241210161.
9
Association of pain and clinical factors on disability and quality of life in systemic sclerosis: A cross-sectional study from Turkish League Against Rheumatism Network.系统性硬化症中疼痛及临床因素与残疾和生活质量的关联:来自土耳其风湿病联盟网络的一项横断面研究
Arch Rheumatol. 2022 Nov 11;38(1):9-21. doi: 10.46497/ArchRheumatol.2023.9243. eCollection 2023 Mar.
10
Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.大麻素化合物作为治疗非癌症皮肤疾病的一种药物治疗选择。
Cells. 2022 Dec 16;11(24):4102. doi: 10.3390/cells11244102.